Literature DB >> 1138538

Lymphocytic choriomeningitis in university hospital personnel. Clinical features.

B E Vanzee, R G Douglas, R F Betts, A W Bauman, D W Fraser, A R Hinman.   

Abstract

Clinical manifestations of lymphocytic choriomeningitis (LCM) virus infection in 15 patients are described. These patients were University Hospital personnel who had had contact with hamsters, subsequently shown to harbor the virus. Fever with striking myalgias, headache and rigors were the most common symptoms. Only 2 of the 15 patients had clinically overt and documented aseptic meningitis. Leuikpenia was observed in 10 of 11 patients and thrombocytopenia in 8 of 8 patients tested. A biphasic illness was seen in eight patients. In a patient who has been exposed to laboratory animals, particularly to hamsters, a nonspecific influenza-like febrile illness accompanied by leukopenia and thrombocytopenia may represent LCM virus infection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138538     DOI: 10.1016/0002-9343(75)90635-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Some observations on hamster-derived human infection with lymphocytic choriomeningitis virus.

Authors:  J Hotchin; W Kinch; E Sikora
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

2.  Hantavirus and arenavirus antibody prevalence in rodents and humans in Trentino, Northern Italy.

Authors:  H Kallio-Kokko; J Laakkonen; A Rizzoli; V Tagliapietra; I Cattadori; S E Perkins; P J Hudson; A Cristofolini; W Versini; O Vapalahti; A Vaheri; H Henttonen
Journal:  Epidemiol Infect       Date:  2005-12-22       Impact factor: 2.451

3.  Isolation of an arenavirus from a marmoset with callitrichid hepatitis and its serologic association with disease.

Authors:  C B Stephensen; J R Jacob; R J Montali; K V Holmes; E Muchmore; R W Compans; E D Arms; M J Buchmeier; R E Lanford
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Mice deficient in STAT1 but not STAT2 or IRF9 develop a lethal CD4+ T-cell-mediated disease following infection with lymphocytic choriomeningitis virus.

Authors:  Markus J Hofer; Wen Li; Peter Manders; Rachael Terry; Sue Ling Lim; Nicholas J C King; Iain L Campbell
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

5.  Lymphocytic choriomeningitis from pet hamster exposure: a local public health experience.

Authors:  H M Maetz; C A Sellers; W C Bailey; G E Hardy
Journal:  Am J Public Health       Date:  1976-11       Impact factor: 9.308

6.  Exposure to lymphocytic choriomeningitis virus, New York, USA.

Authors:  Barbara Knust; Adam Macneil; Susan J Wong; P Bryon Backenson; Aridth Gibbons; Pierre E Rollin; Stuart T Nichol
Journal:  Emerg Infect Dis       Date:  2011-07       Impact factor: 6.883

7.  Envelope exchange for the generation of live-attenuated arenavirus vaccines.

Authors:  Andreas Bergthaler; Nicolas U Gerber; Doron Merkler; Edit Horvath; Juan Carlos de la Torre; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2006-06-02       Impact factor: 6.823

Review 8.  Lymphocytic choriomeningitis virus in southern France: four case reports and a review of the literature.

Authors:  M C Rousseau; M F Saron; P Brouqui; A Bourgeade
Journal:  Eur J Epidemiol       Date:  1997-10       Impact factor: 12.434

9.  Lymphocytic choriomeningitis virus in employees and mice at multipremises feeder-rodent operation, United States, 2012.

Authors:  Barbara Knust; Ute Ströher; Laura Edison; César G Albariño; Jodi Lovejoy; Emilian Armeanu; Jennifer House; Denise Cory; Clayton Horton; Kathy L Fowler; Jessica Austin; John Poe; Kraig E Humbaugh; Lisa Guerrero; Shelley Campbell; Aridth Gibbons; Zachary Reed; Deborah Cannon; Craig Manning; Brett Petersen; Douglas Metcalf; Bret Marsh; Stuart T Nichol; Pierre E Rollin
Journal:  Emerg Infect Dis       Date:  2014-02       Impact factor: 6.883

Review 10.  Overview of acute and chronic meningitis.

Authors:  P K Coyle
Journal:  Neurol Clin       Date:  1999-11       Impact factor: 3.806

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.